# EDGAR Filing Document

**Accession Number:** 0001729214
**File Stem:** 0001171843-25-006496
**Filing Date:** 2025-10
**Character Count:** 3334
**Document Hash:** ef0cd0d09a27051ef2b9465cfc6fa981
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001171843-25-006496.hdr.sgml**: 20251017

**ACCESSION NUMBER**: 0001171843-25-006496

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20251017

**FILED AS OF DATE**: 20251017

**DATE AS OF CHANGE**: 20251017

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** XORTX Therapeutics Inc.
- **CENTRAL INDEX KEY:** 0001729214
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** A1
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-40858
- **FILM NUMBER:** 251398903

**BUSINESS ADDRESS:**
- **STREET 1:** SUITE 2400 - 745 THURLOW STREET
- **CITY:** VANCOUVER
- **STATE:** A1
- **ZIP:** V6E 0C5
- **BUSINESS PHONE:** 403-607-2621

**MAIL ADDRESS:**
- **STREET 1:** SUITE 2400 - 745 THURLOW STREET
- **CITY:** VANCOUVER
- **STATE:** A1
- **ZIP:** V6E 0C5

**UNITED STATES<br> SECURITIES AND EXCHANGE COMMISSION**<br> **Washington, D.C. 20549**<br>**Form 6-K**<br>**REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16<br> UNDER THE SECURITIES EXCHANGE ACT OF 1934**<br>

**For the month of October 2025**

**Commission File Number: 001-40858**

**XORTX Therapeutics Inc.**

**3710 – 33<sup>rd</sup> Street NW, Calgary, Alberta, T2L 2M1**

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ⊠ Form 40-F □

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | | | |
|:---|:---|:---|:---|
|  |  | **XORTX THERAPEUTICS INC.** | **XORTX THERAPEUTICS INC.** |
|  |  | (Registrant) | (Registrant) |
| Date: | October 17, 2025 | By: | */s/ Allen Davidoff* |
|  |  | Name: | Allen Davidoff |
|  |  | Title: | Chief Executive Officer<br>|

---

**<u>EXHIBIT INDEX</u>**

[99.1](exh_991.htm) [Pro-forma Interim Interim Balance Sheet as at September 30, 2025 and October 16, 2025](exh_991.htm)

## Exhibit 99.1

**Exhibit 99.1**

#### XORTX THERAPEUTICS INC.

#### PRO-FORMA INTERIM INTERIM BALANCE SHEET

#### as at September 30, 2025 and October 16, 2025

---

| |
|:---|
| **Assets** |
| **Current** |
| &nbsp;&nbsp;&nbsp;&nbsp;Cash |
| &nbsp;&nbsp;&nbsp;&nbsp;Accounts receivable |
| &nbsp;&nbsp;&nbsp;&nbsp;Prepaid expenses |
| &nbsp;&nbsp;&nbsp;&nbsp;Deferred share issuance costs |
| **Total Current Assets**  |
| **Non-current** |
| &nbsp;&nbsp;&nbsp;&nbsp;Contract payments |
| &nbsp;&nbsp;&nbsp;&nbsp;Acquired assets |
| &nbsp;&nbsp;&nbsp;&nbsp;Intangible assets |
| &nbsp;&nbsp;&nbsp;&nbsp;Property and equipment |
| **Total Assets** |
| **Liabilities** |
| **Current** |
| &nbsp;&nbsp;&nbsp;&nbsp;Accounts payable and accrued liabilities |
| &nbsp;&nbsp;&nbsp;&nbsp;Derivative warrant liability |
| &nbsp;&nbsp;&nbsp;&nbsp;Lease obligation |
| **Total Liabilities** |
| **Shareholders' Equity** |
| Share capital |
| Reserves |
| Obligation to issue shares |
| Accumulated other comprehensive loss) |
| Accumulated deficit) |
| **Total Shareholders' Equity** |
| **Total Liabilities and Shareholders' Equity** |

---